TrialJournal for immunotherapy of cancer2025

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081.

Greg Durm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.